Finall Exam:l NRl 567/l NR567l (Latestl
2025/l 2026l Update)l Advancedl
Pharmacologyl forl thel AGACNPl Guide|l
Questionsl &l Answers|l Gradel A|l 100%l
Correctl (Verifiedl Solutions)-l Chamberlain
Q:l Betal blocker
Answer:
orall ______l ________l therapyl withinl 24l hoursl ofl cardiacl eventl unlessl contraindicated
Q:l Calciuml Channell Blockers
Answer:
Ifl beta-blockersl arel notl tolerated,l consider
Q:l verapamill andl dilatiazem
Answer:
Examplesl ofl calciuml channell blockers
Q:l 162-325l MG
Answer:
,Aspirinl loadingl dosel forl anl NSTEMI
Q:l 600l mg,l 75mgl daily
Answer:
Loadingl dosel ofl PLAVIX
Q:l Eptifibatide
Answer:
Indicatedl forl Acutel coronaryl syndromel andl usedl inl combinationl withl heparin,l aspirin,l
ticlidl andl plavix;l adversel reactions:l bleeding,l hypotension,l thrombocytopenia,l acutel
toxicity:l decreasedl musclel tone,l dyspnea,l lossl ofl rightingl reflex;l baselinel PT/aPTT,l
H&H,l plateletl countl adl monitor;l watchl forl bleeding;l quicklyl reversiblel sol emergencyl
proceduresl mayl stilll bel performedl shortlyl afterl discontinuingl infusion
Q:l Tirofiban
Answer:
Glycoproteinl IIb/IIIal inhibitorl usedl forl highl riskl patientsl withl plannedl PCTA
Q:l ACEsl andl ARBs
Answer:
Reducesl cardiacl remodelingl post-MI,l Improvesl patientl survivall inl thosel withl heartl
failurel orl anteriorl myocardiall infarction
,Q:l Reteplase
Answer:
thrombolyticl agent,l Similarl outcomesl asl alteplasel inl termsl ofl mortalityl NSTEMI
Easierl tol administer
Initiall Bolusl overl 2l minutes,l thenl repeatl thel samel dosel bolusl atl 30l minutes
Q:l Alteplase
Answer:
Initiatesl locall fibrinolysisl byl bindingl tol fibrinl inl al thrombus,l convertingl plasminogenl tol
plasmin
Givenl asl initiall intravenousl bolus,l followedl byl twol separatel infusions
Shortl half-life
Administerl withl concurrentl aspirin,l clopidogrel,l andl anticoagulantl therapyl (unfractionatedl
heparin,l enoxaparin,l fondaparinux)
Q:l Tenecteplase
Answer:
Similarl efficacyl tol Alteplase
Lowerl ratel ofl non-cerebrall bleedingl events
Easierl tol useSinglel bolus,l weight-based
Q:l Fibrinolyticl therapy
Answer:
shouldl bel administeredl withinl thel firstl twol hoursl ofl symptoml onsetl andl isl utilizedl ifl
timelyl PCIl isl notl available.
, Q:l 2
Answer:
Fibrinolyticl therapyl shouldl bel givenl withinl ___l hoursl ofl thel onsetl ofl symptoms.
Q:l duall antiplateletl therapy,l betal blocker,l statinl andl anl ACE/ARB
Answer:
Clinicall practicel guidelinesl indicatel thatl alll patientsl whol havel experiencedl al STEMIl
shouldl bel dischargedl with
Q:l alpha-1
Answer:
adrenergicl receptorsl constrictl bloodl vessels,l constrictl bladderl neck
Q:l beta-1
Answer:
adrenergicl receptorsl increasel hrl contractility,l increasel renin
Q:l beta-2
Answer:
adrenergicl receptorsl relaxl uterus,l dilatel bronchi,l decreasel peristalsis,l andl increasel glucose
2025/l 2026l Update)l Advancedl
Pharmacologyl forl thel AGACNPl Guide|l
Questionsl &l Answers|l Gradel A|l 100%l
Correctl (Verifiedl Solutions)-l Chamberlain
Q:l Betal blocker
Answer:
orall ______l ________l therapyl withinl 24l hoursl ofl cardiacl eventl unlessl contraindicated
Q:l Calciuml Channell Blockers
Answer:
Ifl beta-blockersl arel notl tolerated,l consider
Q:l verapamill andl dilatiazem
Answer:
Examplesl ofl calciuml channell blockers
Q:l 162-325l MG
Answer:
,Aspirinl loadingl dosel forl anl NSTEMI
Q:l 600l mg,l 75mgl daily
Answer:
Loadingl dosel ofl PLAVIX
Q:l Eptifibatide
Answer:
Indicatedl forl Acutel coronaryl syndromel andl usedl inl combinationl withl heparin,l aspirin,l
ticlidl andl plavix;l adversel reactions:l bleeding,l hypotension,l thrombocytopenia,l acutel
toxicity:l decreasedl musclel tone,l dyspnea,l lossl ofl rightingl reflex;l baselinel PT/aPTT,l
H&H,l plateletl countl adl monitor;l watchl forl bleeding;l quicklyl reversiblel sol emergencyl
proceduresl mayl stilll bel performedl shortlyl afterl discontinuingl infusion
Q:l Tirofiban
Answer:
Glycoproteinl IIb/IIIal inhibitorl usedl forl highl riskl patientsl withl plannedl PCTA
Q:l ACEsl andl ARBs
Answer:
Reducesl cardiacl remodelingl post-MI,l Improvesl patientl survivall inl thosel withl heartl
failurel orl anteriorl myocardiall infarction
,Q:l Reteplase
Answer:
thrombolyticl agent,l Similarl outcomesl asl alteplasel inl termsl ofl mortalityl NSTEMI
Easierl tol administer
Initiall Bolusl overl 2l minutes,l thenl repeatl thel samel dosel bolusl atl 30l minutes
Q:l Alteplase
Answer:
Initiatesl locall fibrinolysisl byl bindingl tol fibrinl inl al thrombus,l convertingl plasminogenl tol
plasmin
Givenl asl initiall intravenousl bolus,l followedl byl twol separatel infusions
Shortl half-life
Administerl withl concurrentl aspirin,l clopidogrel,l andl anticoagulantl therapyl (unfractionatedl
heparin,l enoxaparin,l fondaparinux)
Q:l Tenecteplase
Answer:
Similarl efficacyl tol Alteplase
Lowerl ratel ofl non-cerebrall bleedingl events
Easierl tol useSinglel bolus,l weight-based
Q:l Fibrinolyticl therapy
Answer:
shouldl bel administeredl withinl thel firstl twol hoursl ofl symptoml onsetl andl isl utilizedl ifl
timelyl PCIl isl notl available.
, Q:l 2
Answer:
Fibrinolyticl therapyl shouldl bel givenl withinl ___l hoursl ofl thel onsetl ofl symptoms.
Q:l duall antiplateletl therapy,l betal blocker,l statinl andl anl ACE/ARB
Answer:
Clinicall practicel guidelinesl indicatel thatl alll patientsl whol havel experiencedl al STEMIl
shouldl bel dischargedl with
Q:l alpha-1
Answer:
adrenergicl receptorsl constrictl bloodl vessels,l constrictl bladderl neck
Q:l beta-1
Answer:
adrenergicl receptorsl increasel hrl contractility,l increasel renin
Q:l beta-2
Answer:
adrenergicl receptorsl relaxl uterus,l dilatel bronchi,l decreasel peristalsis,l andl increasel glucose
